Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 73

1.

Interim analysis of a real-world precision medicine platform for molecular profiling of metastatic or advanced cancers: MONDTI.

Kieler M, Unseld M, Bianconi D, Waneck F, Mader R, Wrba F, Fuereder T, Marosi C, Raderer M, Staber P, Berger W, Sibilia M, Polterauer S, Müllauer L, Preusser M, Zielinski CC, Prager GW.

ESMO Open. 2019 Jul 17;4(4):e000538. doi: 10.1136/esmoopen-2019-000538. eCollection 2019.

PMID:
31423337
2.

EGFR Controls Hair Shaft Differentiation in a p53-Independent Manner.

Amberg N, Sotiropoulou PA, Heller G, Lichtenberger BM, Holcmann M, Camurdanoglu B, Baykuscheva-Gentscheva T, Blanpain C, Sibilia M.

iScience. 2019 May 31;15:243-256. doi: 10.1016/j.isci.2019.04.018. Epub 2019 Apr 17.

3.

Results of the extended analysis for cancer treatment (EXACT) trial: a prospective translational study evaluating individualized treatment regimens in oncology.

Prager GW, Unseld M, Waneck F, Mader R, Wrba F, Raderer M, Fuereder T, Staber P, Jäger U, Kieler M, Bianconi D, Hoda MA, Baumann L, Reinthaller A, Berger W, Grimm C, Kölbl H, Sibilia M, Müllauer L, Zielinski C.

Oncotarget. 2019 Jan 29;10(9):942-952. doi: 10.18632/oncotarget.26604. eCollection 2019 Jan 29.

4.

EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer.

Martini G, Cardone C, Vitiello PP, Belli V, Napolitano S, Troiani T, Ciardiello D, Della Corte CM, Morgillo F, Matrone N, Sforza V, Papaccio G, Desiderio V, Paul MC, Moreno-Viedma V, Normanno N, Rachiglio AM, Tirino V, Maiello E, Latiano TP, Rizzi D, Signoriello G, Sibilia M, Ciardiello F, Martinelli E.

Mol Cancer Ther. 2019 Apr;18(4):845-855. doi: 10.1158/1535-7163.MCT-18-0539. Epub 2019 Mar 1.

PMID:
30824612
5.

Feasibility of personalized treatment concepts in gastrointestinal malignancies: Sub-group results of prospective clinical phase II trial EXACT.

Unseld M, Mader R, Baumann L, Veraar C, Wrba F, Waneck F, Kieler M, Bianconi D, Berger W, Sibilia M, Müllauer L, Zielinski C, Prager GW.

Chin J Cancer Res. 2018 Oct;30(5):508-515. doi: 10.21147/j.issn.1000-9604.2018.05.04.

6.

A meta-analysis of melanoma risk in industrial workers.

Vujic I, Gandini S, Stanganelli I, Fierro MT, Rappersberger K, Sibilia M, Tosti G, Ferrucci PF, Caini S, De Felici MB, Pagliarello C, Quaglino P, Sanlorenzo M; on behalf of IMI, the Italian Melanoma Intergroup.

Melanoma Res. 2018 Oct 26. doi: 10.1097/CMR.0000000000000531. [Epub ahead of print]

PMID:
30371537
7.

EGFR is required for FOS-dependent bone tumor development via RSK2/CREB signaling.

Linder M, Glitzner E, Srivatsa S, Bakiri L, Matsuoka K, Shahrouzi P, Dumanic M, Novoszel P, Mohr T, Langer O, Wanek T, Mitterhauser M, Wagner EF, Sibilia M.

EMBO Mol Med. 2018 Nov;10(11). pii: e9408. doi: 10.15252/emmm.201809408.

8.

RNA editing of Filamin A pre-mRNA regulates vascular contraction and diastolic blood pressure.

Jain M, Mann TD, Stulić M, Rao SP, Kirsch A, Pullirsch D, Strobl X, Rath C, Reissig L, Moreth K, Klein-Rodewald T, Bekeredjian R, Gailus-Durner V, Fuchs H, Hrabě de Angelis M, Pablik E, Cimatti L, Martin D, Zinnanti J, Graier WF, Sibilia M, Frank S, Levanon EY, Jantsch MF.

EMBO J. 2018 Oct 1;37(19). pii: e94813. doi: 10.15252/embj.201694813. Epub 2018 Aug 7.

9.

Impaired neural stem cell expansion and hypersensitivity to epileptic seizures in mice lacking the EGFR in the brain.

Robson JP, Wagner B, Glitzner E, Heppner FL, Steinkellner T, Khan D, Petritsch C, Pollak DD, Sitte HH, Sibilia M.

FEBS J. 2018 Sep;285(17):3175-3196. doi: 10.1111/febs.14603. Epub 2018 Aug 4.

10.

Afatinib restrains K-RAS-driven lung tumorigenesis.

Moll HP, Pranz K, Musteanu M, Grabner B, Hruschka N, Mohrherr J, Aigner P, Stiedl P, Brcic L, Laszlo V, Schramek D, Moriggl R, Eferl R, Moldvay J, Dezso K, Lopez-Casas PP, Stoiber D, Hidalgo M, Penninger J, Sibilia M, Győrffy B, Barbacid M, Dome B, Popper H, Casanova E.

Sci Transl Med. 2018 Jun 20;10(446). pii: eaao2301. doi: 10.1126/scitranslmed.aao2301.

PMID:
29925635
11.

Liver Cancer Initiation Requires p53 Inhibition by CD44-Enhanced Growth Factor Signaling.

Dhar D, Antonucci L, Nakagawa H, Kim JY, Glitzner E, Caruso S, Shalapour S, Yang L, Valasek MA, Lee S, Minnich K, Seki E, Tuckermann J, Sibilia M, Zucman-Rossi J, Karin M.

Cancer Cell. 2018 Jun 11;33(6):1061-1077.e6. doi: 10.1016/j.ccell.2018.05.003.

12.

Bacterial ghosts as adjuvant to oxaliplatin chemotherapy in colorectal carcinomatosis.

Groza D, Gehrig S, Kudela P, Holcmann M, Pirker C, Dinhof C, Schueffl HH, Sramko M, Hoebart J, Alioglu F, Grusch M, Ogris M, Lubitz W, Keppler BK, Pashkunova-Martic I, Kowol CR, Sibilia M, Berger W, Heffeter P.

Oncoimmunology. 2018 Feb 16;7(5):e1424676. doi: 10.1080/2162402X.2018.1424676. eCollection 2018.

13.

BRAF and MEK Inhibitors Increase PD-1-Positive Melanoma Cells Leading to a Potential Lymphocyte-Independent Synergism with Anti-PD-1 Antibody.

Sanlorenzo M, Vujic I, Floris A, Novelli M, Gammaitoni L, Giraudo L, Macagno M, Leuci V, Rotolo R, Donini C, Basiricò M, Quaglino P, Fierro MT, Giordano S, Sibilia M, Carnevale-Schianca F, Aglietta M, Sangiolo D.

Clin Cancer Res. 2018 Jul 15;24(14):3377-3385. doi: 10.1158/1078-0432.CCR-17-1914. Epub 2018 Apr 12.

14.

Osteopontin-deficient progenitor cells display enhanced differentiation to adipocytes.

Moreno-Viedma V, Tardelli M, Zeyda M, Sibilia M, Burks JD, Stulnig TM.

Obes Res Clin Pract. 2018 May - Jun;12(3):277-285. doi: 10.1016/j.orcp.2018.02.006. Epub 2018 Mar 6.

PMID:
29519755
15.

ADAM17 is required for EGF-R-induced intestinal tumors via IL-6 trans-signaling.

Schmidt S, Schumacher N, Schwarz J, Tangermann S, Kenner L, Schlederer M, Sibilia M, Linder M, Altendorf-Hofmann A, Knösel T, Gruber ES, Oberhuber G, Bolik J, Rehman A, Sinha A, Lokau J, Arnold P, Cabron AS, Zunke F, Becker-Pauly C, Preaudet A, Nguyen P, Huynh J, Afshar-Sterle S, Chand AL, Westermann J, Dempsey PJ, Garbers C, Schmidt-Arras D, Rosenstiel P, Putoczki T, Ernst M, Rose-John S.

J Exp Med. 2018 Apr 2;215(4):1205-1225. doi: 10.1084/jem.20171696. Epub 2018 Feb 22.

16.

EGFR controls bone development by negatively regulating mTOR-signaling during osteoblast differentiation.

Linder M, Hecking M, Glitzner E, Zwerina K, Holcmann M, Bakiri L, Ruocco MG, Tuckermann J, Schett G, Wagner EF, Sibilia M.

Cell Death Differ. 2018 Jun;25(6):1094-1106. doi: 10.1038/s41418-017-0054-7. Epub 2018 Feb 14.

17.

Epidermal Growth Factor Receptor Expression Licenses Type-2 Helper T Cells to Function in a T Cell Receptor-Independent Fashion.

Minutti CM, Drube S, Blair N, Schwartz C, McCrae JC, McKenzie AN, Kamradt T, Mokry M, Coffer PJ, Sibilia M, Sijts AJ, Fallon PG, Maizels RM, Zaiss DM.

Immunity. 2017 Oct 17;47(4):710-722.e6. doi: 10.1016/j.immuni.2017.09.013.

18.

Covalent dimerization of interleukin-like epithelial-to-mesenchymal transition (EMT) inducer (ILEI) facilitates EMT, invasion, and late aspects of metastasis.

Kral M, Klimek C, Kutay B, Timelthaler G, Lendl T, Neuditschko B, Gerner C, Sibilia M, Csiszar A.

FEBS J. 2017 Oct;284(20):3484-3505. doi: 10.1111/febs.14207. Epub 2017 Sep 14.

19.

Hepatocyte-Specific Deletion of EGFR in Mice Reduces Hepatic Abcg2 Transport Activity Measured by [11C]erlotinib and Positron Emission Tomography.

Traxl A, Komposch K, Glitzner E, Wanek T, Mairinger S, Langer O, Sibilia M.

Drug Metab Dispos. 2017 Oct;45(10):1093-1100. doi: 10.1124/dmd.117.077081. Epub 2017 Aug 8.

PMID:
28790147
20.

EGFR in Tumor-Associated Myeloid Cells Promotes Development of Colorectal Cancer in Mice and Associates With Outcomes of Patients.

Srivatsa S, Paul MC, Cardone C, Holcmann M, Amberg N, Pathria P, Diamanti MA, Linder M, Timelthaler G, Dienes HP, Kenner L, Wrba F, Prager GW, Rose-John S, Eferl R, Liguori G, Botti G, Martinelli E, Greten FR, Ciardiello F, Sibilia M.

Gastroenterology. 2017 Jul;153(1):178-190.e10. doi: 10.1053/j.gastro.2017.03.053. Epub 2017 Apr 9.

Supplemental Content

Loading ...
Support Center